AstraZeneca: Esophagitis, Peptic trials

The registry lists 12 Esophagitis, Peptic studies with AstraZeneca as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 1Phase 3 5Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal UlcerCompletedNCT03553563Phase 3Results posted
• A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related DiseasesCompletedNCT02153398Phase 3Results posted
• Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)CompletedNCT01669811Phase 3Results posted
• To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving RabeprazoleCompletedNCT01397084Phase 4Results posted
• Reflux Esophagitis Phase III Study (Maintenance Treatment)CompletedNCT00634114Phase 3Results posted
• Reflux Esophagitis Phase III Study (Initial Treatment)CompletedNCT00633932Phase 3Results posted
• Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical OutcomesCompletedNCT02477475
• BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male SubjectsCompletedNCT01964131Phase 1
• Nexium Capsules RE Maintenance Specific Clinical Experience InvestigationCompletedNCT01562639
• Nexium Capsules Clinical Experience InvestigationCompletedNCT01434485
• Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive EsophagitisCompletedNCT00859287
• NEXIUM® in the Treatment of Moderate and Severe Erosive EsophagitisCompletedNCT00206180Phase 4